Brazil’s ANVISA Globalizes on Class I/II Medtech Regs, Hikes Fees
This article was originally published in Clinica
Executive Summary
New medical technology resolutions issued by Brazil’s healthcare products regulatory agency, ANVISA, are designed to help both the regulator and medtech manufacturers, in terms of simplified processes and speed to market.
You may also be interested in...
Brazil Gives Medtech More Time to Deal With Technical Dossier Rule
Anvisa has extended the deadline for companies to prepare technical dossiers for low-risk medical devices and in vitro diagnostics, giving industry more time to deal with the costs and work involved with complying with the new requirement.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.